You are here

Genzyme

Sanofi’s Viehbacher Rules Out $80-a-Share Offer for Genzyme

Bloomberg

Thu, 10/28/10 - 08:06 am

Chris Viehbacher

In Sanofi-Genzyme Deal, Both Sides Are Dancing Around Bad Information

BNET Pharma

Wed, 10/27/10 - 09:02 am

4 M&A Targets With Notable Open Interest

Seeking Alpha

Sun, 10/24/10 - 01:35 pm

Seattle Genetics

Genzyme Investors Are Urged to Reject Sanofi Offer as Too Low

NY Times, NY

Sat, 10/23/10 - 11:17 am

How High Could a Sanofi Bid for Genzyme Go?

WSJ Online

Sat, 10/23/10 - 10:41 am

Genzyme: Company worth $89 a share

Marketwatch

Fri, 10/22/10 - 01:14 pm

Genzyme makes case for higher Sanofi deal value

Yahoo/Reuters

Fri, 10/22/10 - 11:25 am

Genzyme Drug Should Be Given as Full Dose, EMA Says

Bloomberg

Fri, 10/22/10 - 10:56 am

Fabry's disease

Genzyme's Clolar fails late-stage leukemia study

Yahoo/AP

Wed, 10/20/10 - 12:16 pm

Medicis: Genzyme filed patent infringement lawsuit

Yahoo/AP

Wed, 10/20/10 - 10:51 am

Sanofi gets OK from U.S. authorities for Genzyme bid

Yahoo/Reuters

Wed, 10/20/10 - 09:36 am

Genzyme 3Q: Not Your Run-of-the-Mill Earnings Report

WSJ Online

Wed, 10/20/10 - 09:26 am

Genzyme Corp: Earnings Preview

Yahoo/Zacks.com

Tue, 10/19/10 - 04:20 pm

Genzyme sues drug firm over wrinkle treatment

Boston Globe, MA

Sat, 10/16/10 - 09:18 am

Why Pharmathene Could Go From $2 to $20

Seeking Alpha

Fri, 10/15/10 - 12:34 pm

Emergent BioSolutions

SIGA technologies

Gilead Sciences

Human Genome Sciences

Sanofi Aventis: Clouds Remain Until Genzyme Deal Is Resolved

Seeking Alpha

Fri, 10/15/10 - 10:41 am

Genzyme Says Campath MS Success Helps Justify Higher Sanofi Buyout Offer

Bloomberg

Thu, 10/14/10 - 05:19 pm

multiple sclerosis

Genzyme sees signs of remission in 5-year MS drug data

Fierce Biotech

Thu, 10/14/10 - 11:53 am

multiple sclerosis

Genzyme to vest stock options if acquired

Bizjournals.com

Thu, 10/14/10 - 11:51 am

Is Gilead Sciences a Sell?

Motley Fool

Thu, 10/14/10 - 09:32 am

Gilead Sciences

Pages